Company profile: Galvanize Therapeutics
1.1 - Company Overview
Company description
- Provider of a biomedical platform delivering therapeutic products and services, including Aliya™ PEF System, a pulsed electric field technology for soft tissue ablation in various medical applications such as oncology, and RheOx®, a device targeting chronic bronchitis symptoms by reducing mucus-producing airway cells through pulsed electric fields.
Products and services
- RheOx®: A medical-grade device that targets chronic bronchitis symptoms by reducing mucus-producing airway cells using pulsed electric fields to lessen mucus burden
- Aliya™ PEF System: A platform-scale pulsed electric field technology engineered for soft tissue ablation across various medical applications, including oncology, using pulsed electric fields to ablate targeted soft tissue
- Therapeutic Products and Services: A platform-based biomedical offering that offers therapeutic products and services to deliver healthcare solutions, aligning products and services within a unified platform for healthcare delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Galvanize Therapeutics
ImmunoMet Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer patients, including Lixumistat (IM156), an orally bioavailable small molecule inhibitor of Protein Complex 1 that targets Oxidative Phosphorylation to reduce aberrant cell growth in cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoMet Therapeutics company profile →
Exact Imaging
HQ: Canada
Website
- Description: Provider of 29 MHz micro-ultrasound imaging for real-time targeted prostate biopsies via the ExactVu system, offering high-resolution visualization and enhancements like ExactVu Micro Doppler. Solutions include PRI-MUS protocol for prostate cancer risk assessment, FusionVu for MRI-ultrasound alignment and targeting, and Cognitive Assist for cognitive fusion displaying MRI-identified lesions in real time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Imaging company profile →
Mitomics
HQ: Canada
Website
- Description: Provider of mitochondrial genome-based molecular tests to improve clinical insight and therapeutic decisions that affect patients worldwide, leveraging unparalleled insights into mitochondrial DNA (mtDNA) to develop an extensive, proprietary portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitomics company profile →
OncoResponse
HQ: United States
Website
- Description: Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoResponse company profile →
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Galvanize Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Galvanize Therapeutics
2.2 - Growth funds investing in similar companies to Galvanize Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Galvanize Therapeutics
4.2 - Public trading comparable groups for Galvanize Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →